NNZ-2566 is a drug that intends to reduce brain inflammation. Much of its development has been funded by the military since it is hoped that this drug could reduce the effects of brain trauma. Now the Neuren Corporation is planning clinical trials with children with Rett syndrome and is currently developing the protocol for the trials.
If it helps, this drug could possibly also minimize the progressive effects of MECP2 Duplication Syndrome. Of course, this is a big jump of logic, but it does offer a glimmer of hoe on the horizon. If effective, it would not be a cure but could conceivably help minimize some of the symptoms or slow the progression of the syndrome. More information can be found in this recent news release.
This the 100th post on this blog!
